Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

Open-label, single-group Phase II pilot administering two all-day oral psilocybin sessions (0.3 and 0.4 mg/kg, 4 weeks apart) alongside a 12-week manualised Motivational Enhancement Therapy programme including preparation and debriefing.

Outcomes include drinking behaviour and potential mediators (motivation, self-efficacy, craving), mood and anxiety measures, spiritual dimensions, safety and adverse events, with follow-up to 24 weeks post-treatment.